{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:54:46Z","timestamp":1776873286730,"version":"3.51.2"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Lundbeck (Schweiz) AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40261-026-01537-z","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T07:36:39Z","timestamp":1773560199000},"page":"501-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Tolerability of Vortioxetine in Major Depressive Disorder: A Real-World Study in Switzerland"],"prefix":"10.1007","volume":"46","author":[{"given":"Martin","family":"Kammerer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Hasler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Hochstrasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8226-540X","authenticated-orcid":false,"given":"Alexandra","family":"Sousek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137\u201350.","DOI":"10.1016\/S2215-0366(21)00395-3"},{"issue":"1","key":"1537_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","volume":"19","author":"J Olesen","year":"2012","unstructured":"Olesen J, Gustavsson A, Svensson M, Wittchen HU, J\u00f6nsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155\u201362.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1537_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/14737167.2016.1195688","volume":"16","author":"M Clark","year":"2016","unstructured":"Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):455\u201363.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1537_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.psychres.2016.01.022","volume":"239","author":"JM Kim","year":"2016","unstructured":"Kim JM, Chalem Y, di Nicola S, Hong JP, Won SH, Milea D. A cross-sectional study of functional disabilities and perceived cognitive dysfunction in patients with major depressive disorder in South Korea: the PERFORM-K study. Psychiatry Res. 2016;239:353\u201361.","journal-title":"Psychiatry Res"},{"key":"1537_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2147\/NDT.S159276","volume":"14","author":"D Saragoussi","year":"2018","unstructured":"Saragoussi D, Christensen MC, Hammer-Helmich L, Rive B, Touya M, Haro JM. Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study. Neuropsychiatr Dis Treat. 2018;14:1339\u201350.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1537_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17460441.2019.1546691","volume":"14","author":"X Gonda","year":"2019","unstructured":"Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov. 2019;14(1):81\u20139.","journal-title":"Expert Opin Drug Discov"},{"key":"1537_CR7","unstructured":"Swissmedic. Brintellix\u00ae, film-coated tablets and Brintellix\u00ae, oral drops, solution (vortioxetine). Available from: https:\/\/www.swissmedic.ch\/swissmedic\/de\/home\/humanarzneimittel\/authorisations\/new-medicines\/brintellix---filmtabletten-und-brintellix---tropfen-zum-einnehme.html. (Accessed May 2025)."},{"issue":"2","key":"1537_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/02698811231216320","volume":"38","author":"A Fagiolini","year":"2024","unstructured":"Fagiolini A, Adair M, Buchberg Petersen K, Areberg J, Christensen MC. Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets. J Psychopharmacol. 2024;38(2):156\u201361.","journal-title":"J Psychopharmacol"},{"key":"1537_CR9","unstructured":"Swissmedic. Brintellix\u00ae (vortioxetine). Swiss summary of product characteristics. 2024. Available from: https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&lang=EN&authNr=65937&supportMultipleResults=1. (Accessed Jan 2026)."},{"issue":"9","key":"1537_CR10","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/jm101459g","volume":"54","author":"B Bang-Andersen","year":"2011","unstructured":"Bang-Andersen B, Ruhland T, J\u00f8rgensen M, Smith G, Frederiksen K, Jensen KG, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206\u201321.","journal-title":"J Med Chem"},{"key":"1537_CR11","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2147\/NDT.S199746","volume":"15","author":"G Perini","year":"2019","unstructured":"Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019;15:1249\u201358.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"1537_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1124\/jpet.111.189068","volume":"340","author":"A M\u00f8rk","year":"2012","unstructured":"M\u00f8rk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 1","key":"1537_CR13","first-page":"47","volume":"16","author":"L Westrich","year":"2012","unstructured":"Westrich L, Pehrson A, Zhong H, Nielsen S, Fredericksen K, Stensb\u00f8l TB, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012;16(Suppl. 1):47.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1537_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jad.2017.11.081","volume":"227","author":"MC Christensen","year":"2018","unstructured":"Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. J Affect Disord. 2018;227:787\u201394.","journal-title":"J Affect Disord"},{"issue":"8","key":"1537_CR15","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/npp.2015.52","volume":"40","author":"AR Mahableshwarkar","year":"2015","unstructured":"Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025\u201337.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"1537_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw055","volume":"19","author":"RS McIntyre","year":"2016","unstructured":"McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(10):pyw055.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"1537_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.622","volume":"7","author":"I Florea","year":"2017","unstructured":"Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, et al. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav. 2017;7(3):e00622.","journal-title":"Brain Behav"},{"issue":"5","key":"1537_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1017\/S1461145711001027","volume":"15","author":"E Alvarez","year":"2012","unstructured":"Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589\u2013600.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"1537_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","volume":"22","author":"DS Baldwin","year":"2012","unstructured":"Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482\u201391.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"1537_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","volume":"29","author":"JP Boulenger","year":"2014","unstructured":"Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138\u201349.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"1537_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4088\/JCP.11m07470","volume":"73","author":"N Henigsberg","year":"2012","unstructured":"Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1537_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4088\/JCP.14m09335","volume":"76","author":"PL Jacobsen","year":"2015","unstructured":"Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015;76(5):575\u201382.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1537_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","volume":"26","author":"ME Thase","year":"2016","unstructured":"Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979\u201393.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1537_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.922648","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Cai Y, Hu X, Lu CY, Nie X, Shi L. Systematic review and meta-analysis of vortioxetine for the treatment of major depressive disorder in adults. Front Psychiatry. 2022;13:922648.","journal-title":"Front Psychiatry"},{"issue":"3","key":"1537_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0269881116628440","volume":"30","author":"DS Baldwin","year":"2016","unstructured":"Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242\u201352.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"1537_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euroneuro.2017.06.012","volume":"27","author":"E Vieta","year":"2017","unstructured":"Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. Eur Neuropsychopharmacol. 2017;27(9):877\u201384.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"1537_CR27","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1177\/0269881112441866","volume":"26","author":"JP Boulenger","year":"2012","unstructured":"Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26(11):1408\u201316.","journal-title":"J Psychopharmacol"},{"key":"1537_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2022.02.002","volume":"303","author":"ME Thase","year":"2022","unstructured":"Thase ME, Jacobsen PL, Hanson E, Xu R, Tolkoff M, Murthy NV. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: the RESET study. J Affect Disord. 2022;303:123\u201330.","journal-title":"J Affect Disord"},{"issue":"11","key":"1537_CR29","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"issue":"10","key":"1537_CR30","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/pds.4932","volume":"29","author":"E Baumfeld Andre","year":"2020","unstructured":"Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201\u201312.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1537_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"1537_CR32","unstructured":"Pharma Code. Code of conduct of the pharmaceutical industry in Switzerland; 2003. Revised on 22 May 2025. https:\/\/www.scienceindustries.ch\/en\/article\/12541\/pharma-code. (Accessed Mar 2026)."},{"key":"1537_CR33","volume-title":"ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. Rockville: US Department of Health, Education, and Welfare; 1976."},{"issue":"2","key":"1537_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1017\/S1461145712000727","volume":"16","author":"R Jain","year":"2013","unstructured":"Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313\u201321.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"1537_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4088\/JCP.14m09337","volume":"76","author":"AR Mahableshwarkar","year":"2015","unstructured":"Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry. 2015;76(5):583\u201391.","journal-title":"J Clin Psychiatry"},{"key":"1537_CR36","unstructured":"ClinicalTrials.gov. NCT01255787. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT01255787. (Accessed May 2025)."},{"issue":"6","key":"1537_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ijnp\/pyad018","volume":"26","author":"Z Li","year":"2023","unstructured":"Li Z, Liu S, Wu Q, Li J, Yang Q, Wang X, et al. Effectiveness and safety of vortioxetine for the treatment of major depressive disorder in the real world: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2023;26(6):373\u201384.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1537_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04109-5","volume":"22","author":"E Papalexi","year":"2022","unstructured":"Papalexi E, Galanopoulos A, Kontis D, Markopoulou M, Balta G, Karavelas E, et al. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects. BMC Psychiatry. 2022;22(1):548.","journal-title":"BMC Psychiatry"},{"key":"1537_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.824831","volume":"13","author":"GW Mattingly","year":"2022","unstructured":"Mattingly GW, Ren H, Christensen MC, Katzman MA, Polosan M, Simonsen K, et al. Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the RELIEVE study. Front Psychiatry. 2022;13:824831.","journal-title":"Front Psychiatry"},{"key":"1537_CR40","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2147\/NDT.S358253","volume":"18","author":"G Wang","year":"2022","unstructured":"Wang G, Xiao L, Ren H, Simonsen K, Ma J, Xu X, et al. Effectiveness and safety of vortioxetine for major depressive disorder in real-world clinical practice: results from the single-arm RELIEVE China study. Neuropsychiatr Dis Treat. 2022;18:1939\u201350.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1537_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1075939","volume":"14","author":"SW Moon","year":"2023","unstructured":"Moon SW, Kim JW, Kim DH, Lee KY, Reines EH, Lee M, et al. Safety and effectiveness of vortioxetine for major depressive disorder: real-world evidence from a population-based study in South Korea. Front Psychiatry. 2023;14:1075939.","journal-title":"Front Psychiatry"},{"issue":"9","key":"1537_CR42","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/07067437241245384","volume":"69","author":"RW Lam","year":"2024","unstructured":"Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: r\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes. Can J Psychiatry. 2024;69(9):641\u201387.","journal-title":"Can J Psychiatry"},{"issue":"3","key":"1537_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/13651501.2017.1306082","volume":"21","author":"M Bauer","year":"2017","unstructured":"Bauer M, Severus E, M\u00f6ller HJ, Young AH. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int J Psychiatry Clin Pract. 2017;21(3):166\u201376.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"35","key":"1537_CR44","first-page":"716","volume":"16","author":"E Holsboer-Trachsler","year":"2016","unstructured":"Holsboer-Trachsler E, H\u00e4ttenschwiler J, Beck J, Brand S, Hemmeter U, Keck M, et al. Die somatische Behandlung der unipolaren depressiven St\u00f6rungen: update 2016, Teil 1. Die akutbehandlung depressiver episoden. Schweiz Med Forum. 2016;16(35):716\u201324.","journal-title":"Schweiz Med Forum."},{"key":"1537_CR45","unstructured":"Nationale VersorgungsLeitlinie. Unipolare depression. 2022. Available from: https:\/\/register.awmf.org\/assets\/guidelines\/nvl-005l_S3_Unipolare-Depression_2023-07.pdf. (Accessed Jan 2025)."},{"issue":"5","key":"1537_CR46","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/hup.2424","volume":"29","author":"SA Montgomery","year":"2014","unstructured":"Montgomery SA, Nielsen RZ, Poulsen LH, H\u00e4ggstr\u00f6m L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin\u2013noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470\u201382.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"1537_CR47","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m14780","volume":"84","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Florea I, Pedersen MM, Christensen MC. Head-to-head comparison of vortioxetine versus desvenlafaxine in patients with major depressive disorder with partial response to SSRI therapy: results of the VIVRE study. J Clin Psychiatry. 2023;84(4):23m14780.","journal-title":"J Clin Psychiatry"},{"key":"1537_CR48","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jad.2020.11.106","volume":"283","author":"A Fagiolini","year":"2021","unstructured":"Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI\/SNRI treatment. J Affect Disord. 2021;283:472\u20139.","journal-title":"J Affect Disord"},{"key":"1537_CR49","unstructured":"Swissmedic. Seroquel XR\u00ae (quetiapine). Swiss summary of product characteristics. 2024. Available from: https:\/\/swissmedicinfo.ch\/ViewMonographie. (Accessed May 2025)."},{"issue":"5","key":"1537_CR50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3949\/ccjm.88a.20031","volume":"88","author":"V Modesto-Lowe","year":"2021","unstructured":"Modesto-Lowe V, Harabasz AK, Walker SA. Quetiapine for primary insomnia: consider the risks. Cleve Clin J Med. 2021;88(5):286\u201394.","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"1537_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.31887\/DCNS.2008.10.3\/dnutt","volume":"10","author":"D Nutt","year":"2008","unstructured":"Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 2008;10(3):329\u201336.","journal-title":"Dialogues Clin Neurosci"},{"key":"1537_CR52","unstructured":"Swissmedic. Trittico\u00ae (trazodone) Swiss summary of product characteristics. 2023. Avialble from: https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&lang=EN&authNr=46559&supportMultipleResults=1. (Accessed May 2025)."},{"issue":"8","key":"1537_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082933","volume":"12","author":"R Pelayo","year":"2023","unstructured":"Pelayo R, Bertisch SM, Morin CM, Winkelman JW, Zee PC, Krystal AD. Should trazodone be first-line therapy for insomnia? A clinical suitability appraisal. J Clin Med. 2023;12(8):2933.","journal-title":"J Clin Med"},{"issue":"Suppl. 1","key":"1537_CR54","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jad.2011.03.046","volume":"132","author":"RW Lam","year":"2011","unstructured":"Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011;132(Suppl. 1):S9\u201313.","journal-title":"J Affect Disord"},{"key":"1537_CR55","volume-title":"International classification of diseases. Eleventh revision (ICD-11)","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. International classification of diseases. Eleventh revision (ICD-11). Geneva: World Health Organization; 2022."},{"issue":"3","key":"1537_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cpr.2009.01.005","volume":"29","author":"PE McKnight","year":"2009","unstructured":"McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29(3):243\u201359.","journal-title":"Clin Psychol Rev"},{"issue":"3","key":"1537_CR57","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1017\/S1092852918000913","volume":"24","author":"P Chokka","year":"2019","unstructured":"Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in work productivity and the relationship with cognitive symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2019;24(3):338\u201347.","journal-title":"CNS Spectr"},{"issue":"10128","key":"1537_CR58","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366.","journal-title":"Lancet"},{"issue":"1","key":"1537_CR59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","volume":"28","author":"T Kishi","year":"2023","unstructured":"Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023;28(1):402\u20139.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"1537_CR60","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21r14328","volume":"83","author":"AM Arnaud","year":"2022","unstructured":"Arnaud AM, Brister TS, Duckworth K, Foxworth P, Fulwider T, Suthoff ED, et al. Impact of major depressive disorder on comorbidities: a systematic literature review. J Clin Psychiatry. 2022;83(6):21r14328.","journal-title":"J Clin Psychiatry"},{"key":"1537_CR61","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jad.2022.05.098","volume":"311","author":"DS Baldwin","year":"2022","unstructured":"Baldwin DS, Necking O, Nitschky Schmidt S, Ren H, Reines EH. Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. J Affect Disord. 2022;311:588\u201394.","journal-title":"J Affect Disord"},{"key":"1537_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-0851-4","volume":"16","author":"F Seem\u00fcller","year":"2016","unstructured":"Seem\u00fcller F, Obermeier M, Schennach R, Bauer M, Adli M, Brieger P, et al. Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. BMC Psychiatry. 2016;16:153.","journal-title":"BMC Psychiatry"},{"key":"1537_CR63","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jad.2021.08.108","volume":"295","author":"EC Solis","year":"2021","unstructured":"Solis EC, van Hemert AM, Carlier IVE, Wardenaar KJ, Schoevers RA, Beekman ATF, et al. The 9-year clinical course of depressive and anxiety disorders: new NESDA findings. J Affect Disord. 2021;295:1269\u201379.","journal-title":"J Affect Disord"},{"key":"1537_CR64","unstructured":"National Institute for Health and Care Excellence. Depression in adults: treatment and management. 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/ng222\/chapter\/Recommendations#further-line-treatment. (Accessed Jan 2026)."},{"issue":"10","key":"1537_CR65","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s40263-025-01207-2","volume":"39","author":"B Hochstrasser","year":"2025","unstructured":"Hochstrasser B, Hasler G, Baumann A, Bose R, Reines E, Kammerer M, et al. Effectiveness and tolerability of vortioxetine oral drops versus oral tablets in major depressive disorder: an analysis of a real-world cohort study in Switzerland. CNS Drugs. 2025;39(10):1047\u201359.","journal-title":"CNS Drugs"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01537-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01537-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01537-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:05:08Z","timestamp":1776870308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01537-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01537-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Lundbeck (Schweiz) AG and coordinated by the contract research organisation, ANFOMED GmbH. The sponsor distributed study documentation to clinicians participating in the study in accordance with the Pharma Code (Pharmakodex, 2015). The sponsor also reviewed the manuscript for scientific accuracy. All clinicians received an expense allowance for their involvement in the study, which was based on the time required to complete the relevant tasks (communicate information and complete study documentation) at each study visit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Martin Kammerer holds shares in Roche Pharma AG and Alpine Health AG, and reports speaker honoraria from Lundbeck and Servier. Gregor Hasler reports speaker\/consultant fees from Janssen, Lundbeck, OM Pharma, Salon Pharma, Sanofi, Schwabe, Servier, Sunovion and Takeda. Barbara Hochstrasser is a member of the Advisory Board for vortioxetine of Lundbeck Pharma Switzerland, and a speaker at Lundbeck-sponsored symposia and teaching events for physicians. Axel Baumann is a member of the Swiss Advisory Board on Brintellix and Lundbeck and a speaker in Lundbeck-sponsored symposia. Alexandra Sousek is a full-time employee of Lundbeck (Schweiz) AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"On the 2 April 2017, the Ethics Committee of the Canton of Zurich confirmed that the study protocol did not require specific ethics approval because of its purely observational nature. The study complied with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are not openly available because of reasons of sensitivity and are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualisation: MK. Methodology: MK. Formal analysis and investigation: MK, AB and AS. Writing (review and editing): MK, GH, BH, AB and AS. Supervision: AS. All authors have read and approved the published version of the manuscript and agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}